A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care
- PMID: 37259882
- DOI: 10.1111/apt.17567
A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care
Abstract
Background: The prevalence of irritable bowel syndrome (IBS) is now known to be similar in various geographical regions, but there has been no study directly comparing characteristics of patients with IBS between populations.
Aims: To evaluate clinical and psychological differences between adults with IBS seen in secondary care in the United Kingdom (UK) and Malaysia.
Methods: Age- and sex-matched patients with IBS from a single centre in the UK (Leeds) and two centres in Malaysia (Kuala Lumpur and Kota Bharu), who fulfilled Rome III criteria, were recruited prospectively. Demographic characteristics and gastrointestinal and psychological symptoms were compared between both groups.
Results: A total of 266 (133 UK and 133 Malaysian) age- and sex-matched patients with Rome III IBS were recruited (mean age: 45.1 years Malaysia, vs. 46.5 years UK; 57.9% female). UK patients were more likely to consume alcohol than Malaysian patients (54.1% vs. 10.5%, p < 0.001). Compared with Malaysian patients, UK patients had more frequent abdominal pain, abdominal bloating, meal-related symptoms (p < 0.001 for all), higher symptom scores (mean 268.0 vs 166.0; p < 0.001), greater limitation of activities due to IBS (p = 0.007) and were more likely to report abnormal anxiety scores (p < 0.001). Higher perceived stress (mean 21.3 vs. 19.1, p = 0.014) and gastrointestinal symptom-specific anxiety scores (mean 50.8 vs. 43.0, p < 0.001) were also observed in UK patients. Finally, UK patients had higher somatoform symptom-reporting scores (mean 8.9 vs. 6.9, p < 0.001).
Conclusions: IBS is more severe and is associated with a higher level of psychological symptoms in the UK compared with Malaysian patients in secondary care.
© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never!Aliment Pharmacol Ther. 2023 Aug;58(4):474-475. doi: 10.1111/apt.17620. Aliment Pharmacol Ther. 2023. PMID: 37499102 No abstract available.
-
Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply.Aliment Pharmacol Ther. 2023 Aug;58(4):476-477. doi: 10.1111/apt.17634. Aliment Pharmacol Ther. 2023. PMID: 37499105 No abstract available.
References
REFERENCES
-
- Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150:1393-407.
-
- Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol. 2012;107:912-21.
-
- Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-86.
-
- Chuah KH, Cheong SY, Lim SZ, Mahadeva S. Functional dyspepsia leads to more healthcare utilization in secondary care compared with other functional gastrointestinal disorders. J Dig Dis. 2022;23(2):111-7.
-
- Chuah KH, Beh KH, Mahamad Rappek NA, Mahadeva S. The epidemiology and quality of life of functional gastrointestinal disorders according to Rome III vs Rome IV criteria: a cross-sectional study in primary care. J Dig Dis. 2021;22(3):159-66.